Prof Stephen TaylorBSc, PhD

Leech Professor of Pharmacology

Full contact details
View graph of relations

Overview

Cytotoxic drugs targeting mitosis, including the taxanes and vinca alkaloids, are used widely as chemotherapy agents. For example, in the UK, ~70% of women with ovarian cancer are prescribed the microtubule stabilizer Taxol®. In addition, taxanes and Herceptin® synergise, dramatically improving clinical outcomes among women with HER2-positive breast cancer. However, it is still unclear how exactly these anti-mitotic drugs result in patient benefit. What is clear is that in cell culture, disrupting mitosis activates the spindle assembly checkpoint causing prolonged mitotic arrest. Our research is focused on understanding how this then leads to cell death, with an overall aim of trying to improve the efficacy of these drugs.

Biography

After completing his Bachelors degree in Biochemistry at the University of Manchester, Stephen moved to the Department of Biochemistry in Oxford to pursue his doctoral studies, working in Prof. Ed Southern’s lab. His graduate work focused on developing mammalian artificial chromosomes in order to define the DNA sequences required for human centromere function. After completing his PhD in 1995, Stephen moved to Harvard Medical School funded by a Wellcome Trust Traveling post-doctoral fellowship. There, he worked with Prof. Frank McKeon in the Department of Cell Biology, where he discovered several components of the mammalian spindle assembly checkpoint. In 1998, Stephen moved back to Manchester, funded by a BBSRC David Phillips Fellowship. In 2004 he was awarded a Senior Research Fellowship from Cancer Research UK. In 2009 Stephen renewed his CR-UK Senior Fellowship and was promoted to Professor of Cell Biology. He won the Translational Research Award from the British Association for Cancer Research in 2004, the University of Manchester’s Kilburn-Williams Medal in 2009, and was elected to Academia Europaea in 2010. In 2015, Stephen was awarded the Leech Chair of Pharmacology. During his time in Manchester, Stephen continued to be a pioneer in the spindle checkpoint field, and in collaboration with AstraZeneca described the first inhibitors targeting the Aurora B and Mps1 protein kinases. More recently his research has focused on understanding cell fate in response to anti-mitotic chemotherapy agents.

After completing his Bachelors degree in Biochemistry at the University of Manchester, Stephen moved to the Department of Biochemistry in Oxford to pursue his doctoral studies, working in Prof. Ed Southern’s lab. His graduate work focused on developing mammalian artificial chromosomes in order to define the DNA sequences required for human centromere function. After completing his PhD in 1995, Stephen moved to Harvard Medical School funded by a Wellcome Trust Traveling post-doctoral fellowship. There, he worked with Prof. Frank McKeon in the Department of Cell Biology, where he discovered several components of the mammalian spindle assembly checkpoint. In 1998, Stephen moved back to Manchester, funded by a BBSRC David Phillips Fellowship. In 2004 he was awarded a Senior Research Fellowship from Cancer Research UK. In 2009 Stephen renewed his CR-UK Senior Fellowship and was promoted to Professor of Cell Biology. He won the Translational Research Award from the British Association for Cancer Research in 2004, the University of Manchester’s Kilburn-Williams Medal in 2009, and was elected to Academia Europaea in 2010. In 2015, Stephen was awarded the Leech Chair of Pharmacology. During his time in Manchester, Stephen continued to be a pioneer in the spindle checkpoint field, and in collaboration with AstraZeneca described the first inhibitors targeting the Aurora B and Mps1 protein kinases. More recently his research has focused on understanding cell fate in response to anti-mitotic chemotherapy agents. For more information see the lab website at www.bub1.com.

 

Research Networks and Beacons

Biology, Medicine and Health (BMH) Domains

Related information